Cell therapy · clinical evidence
CAR-T — Understand the evidence before considering treatment
CAR-T is an engineered T-cell approach targeting selected antigens. Some specific products are approved for selected blood cancers and other defined indications in certain jurisdictions.
What is the evidence?
Confirm the exact product, target, jurisdiction, authorized indication and whether the patient meets published eligibility criteria. Solid-tumor applications cannot be inferred from hematology results.
Safety and limitations
Potential serious risks may include cytokine release syndrome, neurotoxicity and infection. Monitoring and management capability must be verified.
What should be assessed?
Pathology and target testing, treatment history, organ function, infections, current medications and the availability of an appropriate specialist team.